Annual Secretarial Compliance Report for FY 2025-2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Bacil Pharma Ltd has submitted its Annual Secretarial Compliance Report for FY 2025-26, reviewed by Practicing Company Secretary Ramesh Chandra Bagdi. The report identifies multiple compliance issues, primarily related to Regulation 33 (LODR) regarding shareholding pattern filings. BSE sought clarifications on four separate occasions (September 2025, November 2025, February 2026, and April 2026) regarding discrepancies in shareholding patterns for various quarters. Additionally, the company failed to submit shareholding pattern in XBRL mode for Q1 FY26 due to 'inadvertent technical and procedural issues', and received a clarification regarding financial results not being signed by an authorized director within the stipulated timeline for Q1 FY26. The company has since filed revised submissions and implemented corrective measures. On a positive note, no penalties or actions were imposed by SEBI or stock exchanges, and the company maintains compliance with secretarial standards, insider trading regulations, and related party transaction requirements.
The recurring clarifications from BSE and XBRL submission delays indicate weak internal compliance controls, though no fines were imposed. This reflects poorly on the company's administrative efficiency but does not suggest any fundamental governance failure.